When a 35-year-old man went in for a cardiology appointment in 2005, thyroid trouble was the last thing on his mind. His cardiologist felt something unusual in his neck and ordered an ultrasound. That single scan set off a chain of discoveries that would later give doctors the chance to act on his children’s inherited cancer risk before either child developed the disease.
That man’s story sits at the heart of a virtual tumor board article published in CA: A Cancer Journal for Clinicians, written by specialists in endocrinology, surgery, oncology, genetics, and radiation medicine. Together, they used his 20-year medical journey to illustrate how, for this one family, a single genetic test reshaped the way a rare form of thyroid cancer called medullary thyroid carcinoma was managed across generations, allowing doctors to spot the inherited risk early and step in before it reached his children as clinical disease.
Medullary thyroid carcinoma is not the common kind of thyroid cancer that usually comes to mind. It grows from a different type of cell, does not respond to the radioactive iodine treatment used for other thyroid cancers, and in as many as one in four cases, it is inherited. Before genetic testing, hereditary forms of the disease were usually recognized only after cancer had already appeared in a family, signaled by a thyroid nodule, rising calcitonin, or a suggestive family history. A genetic test targeting the RET gene gave doctors a way to identify at-risk relatives in advance.
A Cancer Hidden in Plain Sight
When surgeons operated on that 35-year-old man in 2005, they expected to find papillary thyroid carcinoma, the most common and usually treatable form of the disease, based on a needle biopsy done beforehand. Instead, the tissue removed during surgery revealed medullary thyroid carcinoma. The cancer was present in multiple spots across both sides of his thyroid, and his blood showed sharply elevated calcitonin, a hormone produced by the specific cells where this cancer originates. His calcitonin level measured 1,160 picograms per milliliter against a reference range of less than 9.8.
Surgeons removed the thyroid and the lymph nodes from the center of his neck. All 19 removed lymph nodes came back negative for cancer. That was good news. But then came the genetic test.
Results confirmed he carried a mutation in the RET gene at a location called codon 609, a change linked to a hereditary syndrome called multiple endocrine neoplasia type 2A. That finding instantly shifted the story from one man’s cancer to his entire family’s risk.
One Genetic Test Changed Three Generations
A certified genetic counselor worked with the family to understand who else might carry the mutation, a process called cascade testing. That testing identified additional carriers across multiple generations, including the patient’s brother, son, and daughter.
What happened next shows the difference between catching this mutation early versus late. The patient’s brother, not screened until age 37, had already developed metastatic disease by the time the mutation was found in him. His preoperative calcitonin level was 2,450 picograms per milliliter. He underwent total thyroidectomy with bilateral neck dissection and now has persistent disease, currently being treated with a targeted drug called selpercatinib.
Identified only through genetic testing, the patient’s son and daughter underwent preventive thyroid removal at ages 6 and 3, respectively, and are now 25 and 22. Both have had undetectable calcitonin ever since and show no evidence of disease. According to the patient perspective section of the report, learning that his children were carriers felt initially overwhelming and painful, but the clarity provided by testing quickly transformed that fear into a sense of direction and control over the disease.
What 20 Years of Follow-Up Revealed About This Thyroid Cancer
After his initial surgery, the patient achieved undetectable calcitonin levels and stayed in that state for three years. In 2008, calcitonin began rising again, and by 2013, imaging confirmed multiple liver metastases. Even so, the disease advanced unusually slowly. From 2013 to 2025, his calcitonin rose from 850 to 1,820 picograms per milliliter, an increase of roughly 80 picograms per milliliter per year. His calcitonin doubling time, a marker doctors use to gauge how fast the cancer is progressing, stretched from about 13 months in the earliest phase to more than 24 months by the time liver metastases were found in 2013, and beyond 60 months in the years that followed.
Because this patient’s disease was progressing slowly and he had no symptoms, his medical team chose careful monitoring over immediate drug therapy rather than treating based on numbers alone. Then, in 2025, FDG-PET-CT imaging revealed new hypermetabolic lesions, and MRI confirmed bone metastases in the spine, though he remained without symptoms and without any compression of the spinal cord. As of the report, surveillance continues with bisphosphonate support to address the bone involvement.
This 20-year history is both unusual and instructive. It shows that patients with certain RET mutations can experience long periods of stable disease even after metastasis, and that knowing a patient’s genetic profile allows doctors to plan treatment deliberately rather than reactively.
How New Drugs Have Transformed Medullary Thyroid Carcinoma Treatment
For years, doctors treating advanced medullary thyroid carcinoma relied on drugs that targeted multiple cell signals at once. While those medications helped slow the disease, they carried significant side effects including high blood pressure, severe diarrhea, fatigue, and skin problems on the hands and feet. Many patients required dose reductions or had to stop the drugs entirely.
A newer class of drugs, designed to block only the RET protein specifically, has sharply improved outcomes. In two large clinical trials referenced in the paper, LIBRETTO-001 and ARROW, these targeted drugs produced response rates ranging from 69% to 79% in patients with RET-mutated medullary thyroid carcinoma, with far better tolerability than earlier treatments. A critical finding from those trials was that response rates to selective RET inhibitors were similar whether the RET mutation was inherited or acquired by the tumor, meaning the same drugs appear effective for both types of patients.
About half of sporadic MTCs carry somatic RET mutations in the tumor itself, so testing the tumor directly is needed to determine whether these targeted drugs will work for those patients.
Multiple specialists contributed to this report, including pathologists, endocrinologists, surgeons, oncologists, radiation doctors, and a medical geneticist, each examining the same patient’s case through their own lens. That structure was deliberate. No single specialty has the full picture of hereditary MTC.
Radiation therapy plays a narrow but meaningful role here. Because this cancer does not absorb radioactive iodine the way common thyroid cancers do, external radiation is reserved for specific situations: patients with high-risk features after surgery, tumors that could not be fully removed, or painful bone and spinal metastases. In this patient’s case, with bone metastases detected but no pain or neurological symptoms, the team opted to hold radiation in reserve for future need.
Studies cited in the paper show that countries where genetic screening became routine saw the average age of MTC diagnosis drop by years or even decades. In a German cohort, the average age at diagnosis decreased from 35.6 to 23.0 years after routine screening began. In a Norwegian study, the proportion of patients who achieved remission increased from 50% to 89% following the introduction of systematic genetic testing.
